Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with T2D Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis

The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).